Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis

Diagnostic Pathology

Qing Zhu¹  Jianying Zhang¹  Lei Wu¹  Hao Wang¹  Long Jin¹  Gui-hua Jin¹  Xia Zhou¹  Jun-lan Wang¹  Su-xia Han¹  Xia Ying¹ 

[1] Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shannxi, PR China

关键词: Serum biomarkers;    Matri-assisted laser desorption/ionization time-of-flight mass spectrometry;    Magnetic beads;    Liver cirrhosis;    Chronic hepatitis;    Hepatocellular carcinoma;   

Others  :  805808
DOI  :  10.1186/1746-1596-8-130

 received in 2013-04-02, accepted in 2013-07-23,  发布年份 2013

【 摘 要 】

Background

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world,and the identification of biomarkers for the early detection is a relevant target. The purpose of the study is to discover specific low molecular weight (LMW) serum peptidome biomarkers and establish a diagnostic pattern for HCC.

Methods

We undertook this pilot study using a combined application of magnetic beads with Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technique and ClinPro Tools v2.2 to detect 32 patients with HCC, 16 patients with chronic hepatitis (CH), 16 patients with liver cirrhosis (LC) and 16 healthy volunteers.

Results

The results showed 49, 33 and 37 differential peptide peaks respectively appeared in HCC, LC and CH groups. A Supervised Neural Network (SNN) algorithm was used to set up the classification model. Eleven of the identified peaks at m/z 5247.62, 7637.05, 1450.87, 4054.21, 1073.37, 3883.64, 5064.37, 4644.96, 5805.51, 1866.47 and 6579.6 were used to construct the peptides patterns. According to the model, we could clearly distinguish between HCC patients and healthy controls as well as between LC or CH patients and healthy controls.

Conclusions

The study demonstrated that a combined application of magnetic beads with MALDI-TOF MB technique was suitable for identification of potential serum biomarkers for HCC and it is a promising way to establish a diagnostic pattern.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1503629821958720 webcite.

【 授权许可】

   
2013 Ying et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:187-196.
• [2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Establishment of world-wide burden of cancer in,GLOBCAN 2008. Int J Cancer 2008, 2010(127):2893-2917.
• [3]Kew MC: Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol 2010, 58:273-277.
• [4]Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N: Hepatocellular carcinoma. An overview. Ann Hepatol 2006, 5:16-24.
• [5]EI-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:s27-s34.
• [6]EI-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
• [7]Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M: Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011, 21:401-416.
• [8]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
• [9]Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Berloco PB, Rossi M, Levi Sandri GB, Frattarol FM: Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinomarecurrence after surgery: a brilliant star raises again. Int J Hepatol 2012, 2012:893103.
• [10]Sherman M: Alphafetoprotein: an obituary. J Hepatol 2001, 34:603-605.
• [11]Kobeisy MA, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM: Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. Arab J Gastroenterol 2012, 13:49-53.
• [12]Wojtowicz-Chomicz K, Cichoz-Lach H, Lis E, Kowalik A, Slomka M: Evaluation of alpha-fetoprotein concentration in patients with chronic liver diseases. Polski merkuriusz lekarski 2012, 32:374-377.
• [13]El-Aneed A, Banoub J: Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients. Anticancer Res 2006, 26:3293-3300.
• [14]Dai Y, Hu C, Wang L, Huang Y, Zhang L, Xiao X, Tan Y: Serum peptidome patterns of human systemic lupus erythematosus based on magnetic bead separation and MALDI-TOF mass spectrometry analysis. Scand J Rheumatol 2010, 39:240-246.
• [15]Kawashima Y, Fukutomi T, Tomonaga T, Takahashi H, Nomura F, Maeda T, Kodera Y: High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. J Proteome Res 2010, 9:1694-1705.
• [16]Fan NJ, Gao CF, Zhao G, Wang XL, Liu QY: Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol 2012, 7:45. BioMed Central Full Text
• [17]Yang J, Song YC, Song TS, Hu XY, Guo YM, Li ZF, Dang CX, Huang C: Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC). J Clin Lab Anal 2012, 26:148-154.
• [18]Yao N, Chen H, Lin H, Deng C, Zhang X: Enrichment of peptides in serum by C(8)-functionalized magnetic nanoparticles for direct matrix-assisted laser desorption/ionization time-of-flignt mass spectrometry analysis. J Chromatogr A 2008, 1185:93-101.
• [19]Liu LH, Shan BE, Tian ZQ, Sang MX, Ai J, Zhang ZF, Meng J, Zhu H, Wang SJ: Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2010, 48:855-861.
• [20]He AL, Bai J, Huang C, Yang J, Zhang WG, Wang JL, Yang Y, Zhang PY, Zhou FL: Detection of serum tumor markers in multiple myeloma using the CLINPROT system. Int J Hematol 2012, 95:668-674.
• [21]Song QB, Hu WG, Wang P, Yao Y, Zeng HZ: Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin 2011, 32:1537-1542.
• [22]De Noo ME, Deelder A, van der Werff M, Ozalp A, Mertens B, Tollenaar R: MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 2006, 29:501-506.
• [23]Liu Y, Wang J, Lin XY, Xu HT, Qiu XS, Wang EH: Inflammatory angiomyolipoma of the liver: a rare hepatic tumor. Diagn Pathol 2012, 7:122. BioMed Central Full Text
• [24]Mohamed AA, Nada OH, EI Desouky MA: Implication of protein kinase R Gene quantification in hepatitis C Virus Genotype 4 induced Hepatocarcinogenesis. Diagn Pathol 2012, 7:103. BioMed Central Full Text
• [25]Hajosi-Kalcakosz S, Dezso K, Bugyik E, Bodor C, Paku S, Pavai Z, Halasz J, Schlachter K, Schaff Z, Nagy P: Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol 2012, 7:86. BioMed Central Full Text
• [26]Guo X, Zhao J, Peng R, Li H, Zhang J, Sun T, Zou L, Lu Xiong L: L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival. Diagn Pathol 2012, 7:96. BioMed Central Full Text
• [27]Lu J, Huang Y, Wang Y, Li Y, Zhang Y, Wu J, Zhao F, Meng S, Yu X, Ma Q, Song M, Chang N, Bittles AH, Wang W: Profiling plasma peptides for the identification of potential ageing biomarkers in Chinese Han adults. PLoS One 2012, 7:e39726.
• [28]Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH: Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005, 51:2236-2244.
• [29]Sui W, Dai Y, Zhang Y, Chen J, Liu H, Huang H: Proteomic profiling of nephritic syndrome in serum using magnetic bead based samplefractionation & MALDI-TOF MS. Indian J Med Res 2012, 135:305-311.
• [30]Looi KS, Nakayasu ES, De Diaz RA, Tan EM, Almeida IC, Zhang JY: Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 2008, 7:4004-4012.
• [31]Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA: Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009, 87:143-152.
• [32]Liu T, Xue R, Huang X, Zhang D, Dong L, Wu H, Shen X: Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Acta Biochim Biophys Sin 2011, 43:542-550.